Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2015; 140(23): 1775
DOI: 10.1055/s-0041-107750
DOI: 10.1055/s-0041-107750
Fachwissen
Pro & Contra
Pneumokokken-Impfung für Erwachsene unter 60 Jahren? Ja
Pneumococcal Vaccination for Adults – starting before 60? ProFurther Information
Publication History
Publication Date:
03 November 2015 (online)
Die ambulant erworbene Pneumonie (CAP) ist die häufigste Infektion, die in Deutschland zu einer Hospitalisierung führt, und Pneumokokken sind ihr mit Abstand häufigster Erreger. Sie verursachen zwischen 12–85 % aller CAP-Fälle in Europa [9]. Auch in Deutschland sind Pneumokokken mit 30 % der häufigste CAP-Erreger [7].
-
Literatur
- 1 Andrews NJ, Waight PA, George RC et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30: 6802-6808
- 2 Bonten MJ, Huijts SM, Bolkenbaas M et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372: 1114-1125
- 3 Ewig S, Birkner N, Strauss R et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64: 1062-1069
- 4 Kuhlmann A, Theidel U, Pletz MW et al. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev 2012; 2: 4
- 5 Mangen MJ, Rozenbaum MH, Huijts SM et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J 2015;
- 6 Oviedo-Orta E, Li CK, Rappuoli R. Perspectives on vaccine development for the elderly. Curr Opin Immunol 2013; 25: 529-534
- 7 Pletz MW, von Baum H, van der Linden M et al. The burden of pneumococcal pneumonia – experience of the German competence network CAPNETZ. Pneumologie 2012; 66: 470-475
- 8 Schnoor M, Hedicke J, Dalhoff K et al. Approaches to estimate the population-based incidence of community acquired pneumonia. J Infect 2007; 55: 233-239
- 9 Torres A, Blasi F, Peetermans WE et al. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis 2014; 33: 1065-1079
- 10 Pfizer. Fachinformation zu Prevenar 13 Injektionssuspension. https://www.pfizermed.de/fileadmin/produktdatenbank/pdf/012126_freigabe.pdf Letzter Zugriff am 26.10.15